Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It looks like they filed an 8kand hired a public relations firm. Maybe good things are coming and we.The rest of the small biotechs are soaring about
time we get some respect
Someone posted that a review of 60 small biotechs public companies that completed phase 2 trials for their drugs the median market cap was valued at $412M the mean market cap was $230M.
It is interesting that Portages 35 percent interest. in Biohaven with several phase d2 or better drugs that have orphan status is valued for much less.
Well in all these years they didn't go bankrupt and are still operating.
Doctors are scientists not financial geniuses and the responsibilities of being a CEO are sometimes daunting in light of
continual competition against competitors that are well funded and much bigger
in terms of R&D and competing with other drugs in the marketplace ,the FDA and the litigation aspects of getting past drug patents.Now they have a better team with the deals that they have inked,their new plant,and being cashed up to dovetail when collect revenues or royalties from actual drug sales. Once they get all six cylinders firing all at once we will all be rewarded when the plan comes together.
Development revenue,milestones,sales royalties,
mfg revenues of their drugs and contract revenues
This Co. has not diluted as other companies have and stingy on their expenses and etc. After the Indian CEO
nothing happened. Now he has a good team to move this Co forward. The have inked deals that take time,their cheap loan for their plant to manufacture and keep
these profits in house pending the alorovals,their recent allowance for ER bodes well to expand their reach bodes well.If they get any of these to market like Cialis and revenues coming it it will be transformative to the bottom line.
I was hoping their litigation appeal on suboxone would rule in our favor would help a great deal. Their research and Devon mentioned team must be working very hard as well as their mfg team and their commercialization team. Only time and patience will tell
MMK was to provide manufacturing and development money for their 3 licensed drugs. Wondering when that will start.
IPCI let's roll!
I wonder when we will get news. Each day we get close and closer.
How are we doing on the TASE today?
Biohaven has licensed 300. prodrugs
in addition to their 3 late stage orphan drugs. Only time will tell if anymore escape from the lab. How many is anybody guess. Getting g to this stage in the short time they have been in existence speaks volumes and raising $80 M is not a small feat.
The PPS and the people in the know
braced them selves for the drop to 35 percent ownership in Biohaven after
the $80 M funding. Investors perceived this as being a negative impact on the stock but we really gained.
value
49percent of market value before funding $130 M equals $63M
35 percent of $130 plus $80 M cash equals $210 M equals $73 M
Net Gain $10 M
The MMS are clearly in control here.
to bring it down maybe in advance of the company or any of their invested companies making a stausannpuncement on progress and future milestones.
I would thought it would hold up better
but it is thinly traded
They have three drugs with orphan designations one due in August and don't know on the other two.
go to seekingalpha.com and sign up
Pls see messages concerning Portage and sentient Biological on Seeking Alpha
Someone on another board emailed Brian Miller CEO of Sentient Biological who deals in using MSCS for delivery biological
using their drug delivery platform for kidney dialysis.Company patients.
I SINCE they are early and pretty IND I suspect it will be a IND filing.
Check out their website to see what they do
I wonder how they are making out with the litigation on subox an one.? anyone have any idea of where we stand on this last patent?
I am told that their 20 percent owned Co. Sentient Biological will be announcing some news soon
Biohaven also owns part of Klepto run by
one of the top doctors from Yale New Haven. Wondering if any of the $80 M funding that was oversubscribed was reinvested in them. Since Biohaven is private they are not obligated to release any information on how they will use the funds
They were three 1 Million share days
then traded around 600 K and then 200K.
It either mgt buying more as they own more than 5p percent or the MMS since there was no news except maybe the
$80 capital raise of Biohaven
Reservologix met with the FDA to redesign the phase 2a trial into two parts for kidney dialysis.Company intends to file their IND
in 2017.
They ran it up into the 2os and now couldn't hold because there isn't news on their progress. I bought a small chunk in the 20s good thing I didn't buy more.
Don't know where it will bottom out and will be watching until results come out in from BiohavenAugust on SCA. Don't know when the results of the other trial will be.
I imagine when Biohaven starts other trials we may get a little bump .
On another forum someone valued the Stock at $4.50 Half assigned to Biohaven
and the other half to PPL,Sentinelnand Eyegem.However I think PPL should valued more as it can apply across other indicatuons. They suggested a reverse split to get onto a bigger wxchange to raise funds.I think they would go IPO when the time is right for each of these companies.Think we will have to wait till August to see some results from Biohaven s trial. Don't know about the completion of the other trial. or other news that can be catalysts.
Now that this Co has restructured their debt. What is the status of their drug in terms of approval or phase drug triak.
With all the indications that this drug seems to affect with a good safety profile
I am surprised that the stock is not higher. Seems like it maybe too early for anyone to take notice. They had good results in kidney disease and was waiting for a peer review report on this..Anyone have any opinions on this?
Hi I read some of the details of the merger that looks quite complicated. Does anyone have an opinion of whether this is go or bad for TBIO shareholdrfs?
They made a lot of positive changes .
They will reduce their rent by $1.5 M per year starting in October. Award of the First Net contracts to start in April. Company already had 2 first net products and bolt on hardened battery packs and enclosures for this matket.They had a lot of software licensing business that they were booking
but has to spread over the term.
Great positive cash flow actions and increase in dross profit margins to 40 percent from the 30s.
Funny. IGXT goes up $.01 and it's new partner who is paying Igxt money to develop their cannabis drug goes uo $.05
Kind of backwards isn't it? Any comments?
Anyone know any reason for today's movement.I like it!
It looks like there is Feb 2 conference. Any changes to the new presentation?
I am not sure whether mgt is buying this or the mms causing these 1M share days and then dropping back to 6o0K days and then to 200K.most of these Canadian biotechnology stocks are under the radar and don't get the respect it would have if was on NasDaq and takes a long time to form the base. I will continue to buy .
as I like their prospects.
We had a nice move to hit $.16 with less than 1M share volume.Maybe the word is getting out for some chillies.
It looks like the CEO and CSO recently bought more shares in the market at $1.18
must have a good idea of where the stock is heading
It seems their drug RV _208 has many possibilities. What indication is this futility analysis for? I know they were in Phase 3 for DB THAT I think the results will not be available until late 2018 early 2019
Does anyone know when earnings are due Out
and if anyone can get any info on progress in the UK. They said France was a problem
as they didn't want to cut their prices there until they can get the rest of Europe onboard.Also don't know what kind of progress their distributor in the Middle East to get reimbursement and sales moving
The newsreel aseptic was good though it was Only phase 1 study for CKD while
they are working phase 3 for DB.
Nibbled on a small stake then it immediately went down.I wonder how long it is going to take to get peer review paper to give their findings more legs.
Recent phase 2_3 filing Jan 9 for Bhn_0223. Biggest volume ever over 1Mshares. at 1 PM Will this be a 2M share day?
Nice volume nice price movement in a down biotechnology market. News must be coming soon looks like they are getting locked and loaded
Good day for us today in a down market
for biotechnology stocks.
Hopefully it is a the start of good times to come.
It seems like it takes a lot of volume to move this baby
I was looking at the territories that Aurina has licensed with their lead drug.
It does not include Canada,Israel, China ,Taiwan,South Africa.
I hope they can in license with perhaps
a territory like Japan
This drug was originally with Vifor and part of their mgt that went from A sperverva to Isotechnika to merge with Aurina with their ASTM studies of Lupus and other disease conditions associated .
Originally the drug was to be for kidney transplantation. So it seems they have a depth of experience in this area
I don't know the answer to that question. .as Dr Couric runs both PTGEF and Biohaven.
Each of these companies can become valuable as they mature.
Whether they go public or IPO each one
or have a reverse split based upon their structure I don't think will hapoen
Yes I also own igxt and Luke the fact Dr Zerbe has finally got the horses together
to move their platform forward., have the
manufacturing facilities and platform technology to repurpose existing drugs
and have signed up various partners to do so.
Dr Zerbe seems to be very financially conservative that I like without excessive dilution
Waiting to hear the resolution on their suboxone film ,filing Riza port withe US FDA and signing up a partner for Tadafil (Cialis) ,moving Montel use forward for dementia and signing up new partners.
PTGEF also owns 100 percent of PPL that houses their cell transporter technology platform, also they own part of Sentinel part of Biohaven and now the spinoff
of the ophthalmology company with Dr Littman for dry eye disease.
As the details of the $80 M raise was sketchy I noticed Dr Bailey bought part of it and Ven rock not sure if Portage bought any of it and whether they unlicensed their two phase 3 drugs to PFE and BGS
as there is no definitive breakdown as to
how this was structured.
Yes it is difficult value all of these portions of each of these companies and when PTGEF will get any respect by Mr market
Though I think that the catalysts will be
the results of these two Phase 3 studies by Biohaven .
I don't know how ptgef can raise additional equity capital as there is a lot of stock outstanding. After these catalysts they would have a better chance unless they grow each of these companies and then sell their stakes.